DaVita (NYSE:DVA) Sets New 1-Year Low on Analyst Downgrade

DaVita Inc. (NYSE:DVA)’s stock price reached a new 52-week low during mid-day trading on Tuesday after Truist Financial lowered their price target on the stock from $140.00 to $128.00. Truist Financial currently has a hold rating on the stock. DaVita traded as low as $111.43 and last traded at $113.19, with a volume of 213842 shares traded. The stock had previously closed at $113.94.

A number of other research analysts also recently weighed in on the company. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research note on Saturday, October 11th. UBS Group reiterated a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a report on Monday, December 29th. Cowen restated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. Finally, Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a report on Friday, November 28th. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $145.60.

Institutional Investors Weigh In On DaVita

Several hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of DaVita by 59.1% during the fourth quarter. GAMMA Investing LLC now owns 2,371 shares of the company’s stock valued at $269,000 after acquiring an additional 881 shares during the last quarter. Hudson Bay Capital Management LP grew its holdings in shares of DaVita by 55.5% in the third quarter. Hudson Bay Capital Management LP now owns 2,613 shares of the company’s stock worth $347,000 after acquiring an additional 933 shares during the period. Allworth Financial LP grew its position in shares of DaVita by 311.7% during the 3rd quarter. Allworth Financial LP now owns 564 shares of the company’s stock valued at $75,000 after acquiring an additional 427 shares during the period. Swiss Life Asset Management Ltd increased its holdings in DaVita by 4.3% in the 3rd quarter. Swiss Life Asset Management Ltd now owns 7,278 shares of the company’s stock worth $967,000 after acquiring an additional 300 shares in the last quarter. Finally, CIBC Private Wealth Group LLC lifted its position in shares of DaVita by 19.7% in the third quarter. CIBC Private Wealth Group LLC now owns 2,628 shares of the company’s stock valued at $349,000 after acquiring an additional 432 shares in the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Stock Performance

The company has a market capitalization of $7.84 billion, a P/E ratio of 11.44, a P/E/G ratio of 0.71 and a beta of 0.99. The business’s fifty day simple moving average is $117.93 and its 200-day simple moving average is $129.35.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. During the same period in the previous year, the firm earned $2.59 earnings per share. The company’s revenue was up 4.8% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.